Document is current
Any future updates will be listed below
-
Authors
Yokote, Koutaro
Ota, Riku https://orcid.org/0000-0002-6379-4376
Wada, Shogo
Matsuda, Hiroyuki
Filomeno, Ronald
-
Funding
Funding for this research was provided by:
Novo Nordisk Pharma
- License Information
-
More Information
Article History
Received: 17 May 2024
Accepted: 28 June 2024
First Online: 22 July 2024
Declarations
:
: Koutaro Yokote is not an employee of Novo Nordisk Pharma Ltd. but was paid a fee for his guidance and status in this project as a key opinion leader. Additionally, his remunerations or grants/scholarships were paid for by the following companies or for-profit organizations in the past 3 years (2020 to 2023) to attend meetings (presentations, advice, etc.), including daily allowances and lecture fees, for time and effort: Abbott Japan LLC., Bayer Yakuhin, Ltd., Boehringer Ingelheim, Inc., Daiichi Sankyo Co., Ltd., Kowa Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., MSD Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma Ltd., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., Sumitomo Dainippon Pharma Co., Ltd., Sumitomo Pharma Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. Riku Ota was an employee of Novo Nordisk Pharma Ltd. at the time of the analysis and is now an employee of Novo Nordisk A/S. Shogo Wada is an employee of Novo Nordisk Pharma Ltd. Hiroyuki Matsuda and Ronald Filomeno are employees of IQVIA Solutions Japan G.K.; IQVIA Solutions Japan G.K. received consulting fees from Novo Nordisk Pharma Ltd. for this project.
: This review article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
